Highlighting the event is the immersive simulation, “Seeing Beyond the Ordinary and Repairing Damages,” led by world-renowned ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

It's a daycare procedure and doesn't require hospitalisation. However, it is an expensive treatment. Will my health insurance ...

Diabetes affects millions worldwide, and while most know about its impact on blood sugar and organ health, vision loss ...

This condition is called diabetic retinopathy. In its early stages ... making regular eye exams crucial for early detection ...

Experiencing fatigue, blurred vision, and unexplained weight loss, a young man sought medical consultation and was informed ...

The implementation of AIDRSS offers transformative implications for DR screening in India, particularly in rural and ...

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

Insurance coverage for intravitreal injections, an essential treatment for diabetic retinopathy, depends on the specific terms and conditions of an individual’s health insurance policy.